Roche’s Illumina Bid May Spur Buying in DNA Test Land Grab

Less than 10 years after the first human genome was decoded, Roche Holding AG’s hostile $5.7 billion bid for Illumina Inc. may spark additional deals as companies race to bring DNA scanning into routine medical use.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.